These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Umbilical cord blood as a hematopoietic stem cell source in transplantation for pediatric sickle cell disease: current challenges and strategies. Malhotra M; Shenoy S Transfus Apher Sci; 2022 Oct; 61(5):103554. PubMed ID: 36096996 [TBL] [Abstract][Full Text] [Related]
8. Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial. Abraham A; Cluster A; Jacobsohn D; Delgado D; Hulbert ML; Kukadiya D; Murray L; Shenoy S Biol Blood Marrow Transplant; 2017 Sep; 23(9):1587-1592. PubMed ID: 28578010 [TBL] [Abstract][Full Text] [Related]
12. Hematopoietic stem cell transplantation and cellular therapy in sickle cell disease: where are we now? Tanhehco YC; Bhatia M Curr Opin Hematol; 2019 Nov; 26(6):448-452. PubMed ID: 31483336 [TBL] [Abstract][Full Text] [Related]
13. Newer Modalities and Updates in the Management of Sickle Cell Disease: A Systematic Review. Patel ZV; Prajjwal P; Bethineedi LD; Patel DJ; Khullar K; Patel H; Khatri K; Marsool MDM; Gadam S; Aleti S; Amir O J Blood Med; 2024; 15():435-447. PubMed ID: 39286637 [TBL] [Abstract][Full Text] [Related]
14. An update review of new therapies in sickle cell disease: the prospects for drug combinations. Lugthart S; Ginete C; Kuona P; Brito M; Inusa BPD Expert Opin Pharmacother; 2024 Feb; 25(2):157-170. PubMed ID: 38344818 [TBL] [Abstract][Full Text] [Related]
15. An expert review of voxelotor for the treatment of hemolytic anemia in patients with sickle cell disease: 'bridging the gap between laboratory data and patient related outcomes'. Inusa BPD; Mnika K; Babiker S Expert Rev Hematol; 2023; 16(8):585-591. PubMed ID: 37329253 [TBL] [Abstract][Full Text] [Related]
16. Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review. Dick MH; Abdelgadir A; Kulkarni VV; Akram H; Chatterjee A; Pokhrel S; Khan S Cureus; 2022 May; 14(5):e24920. PubMed ID: 35706735 [TBL] [Abstract][Full Text] [Related]
17. Advances in the Treatment of Sickle Cell Disease. Kapoor S; Little JA; Pecker LH Mayo Clin Proc; 2018 Dec; 93(12):1810-1824. PubMed ID: 30414734 [TBL] [Abstract][Full Text] [Related]
18. Development of curative therapies for sickle cell disease. Tanhehco YC; Nathu G; Vasovic LV Front Med (Lausanne); 2022; 9():1055540. PubMed ID: 36507504 [TBL] [Abstract][Full Text] [Related]
19. Modeling the public health impact of voxelotor in the management of sickle cell disease in France. Galacteros F; Ethgen O; Beillat M PLoS One; 2023; 18(9):e0291211. PubMed ID: 37703228 [TBL] [Abstract][Full Text] [Related]
20. Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine. Migotsky M; Beestrum M; Badawy SM Pharmacy (Basel); 2022 Sep; 10(5):. PubMed ID: 36287444 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]